SCHEMBL1401159

SCHEMBL1401159

N[C@@H](Cc1c[nH]c2ccccc12)C(=O)Oc1ccccc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.71
MAPT P10636 2/20 0.71
MEN1 O00255 2/20 0.71
KMT2A Q03164 2/20 0.71
LMNA P02545 1/20 0.71
MPO P05164 1/20 0.71
TSHR P16473 1/20 0.71
BLM P54132 1/20 0.71
PMP22 Q01453 1/20 0.71
HIF1A Q16665 1/20 0.71
TACR1 P25103 2/20 0.61
SMN1; SMN2 Q16637 1/20 0.57
APAF1 O14727 1/20 0.56
POLB P06746 1/20 0.56
RECQL P46063 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
SCN9A Q15858 3/20 0.55
FAAH O00519 1/20 0.55
HTR2A P28223 2/20 0.54
ADRB1 P08588 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7775133 1.00 KDM4E (0.71) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL27582874 0.90 MEN1 (0.61) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL29233343 0.90 MAPT (0.61) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL6032937 0.90 KMT2A (0.71) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL597229 0.90 KMT2A (0.71) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL1239230 0.89 MEN1 (0.59) KDM4EMAPTMEN1KMT2ALMNA
Phenylalanine SCHEMBL10381280 0.89 KMT2A (0.70) KDM4EMAPTMEN1KMT2ALMNA
Tryptophan SCHEMBL28205631 0.88 KMT2A (0.65) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL6535365 0.88 MEN1 (0.58) KDM4EMAPTMEN1KMT2ALMNA
SCHEMBL6535879 0.88 MEN1 (0.58) KDM4EMAPTMEN1KMT2ALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11845808-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases JANSSEN BIOTECH, INC. (US) 2023-12-19 US claimed
EP-1497452-B1 METHODS FOR MEASURING ENZYME ACTIVITY GE HEALTHCARE UK LTD (GB) 2011-03-02 EP claimed
CN-112708589-B Genetically engineered bacterium, construction method thereof and application thereof in fermentation production of 5-hydroxytryptophan 南京工业大学 2023-12-22 CN disclosed
CN-116751696-A Yarrowia lipolytica engineering bacterium for biosynthesis of 5-hydroxy beta-indolylalanine, construction and application thereof 河北维达康生物科技有限公司 2023-09-15 CN disclosed
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD. (CN) 2021-12-09 US disclosed
EP-3858813-A1 QUINOLONE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITED ACTIVITY Shenzhen Chipscreen Biosciences Co., Ltd. (CN) 2021-08-04 EP disclosed
CN-108101978-B The Tyr-Pro-Trp-Phe-NH2 analog and its synthetic method of the esterification modification of C- terminal aromatic and application 哈尔滨工业大学 2018-12-11 CN disclosed
CN-108101978-A The Tyr-Pro-Trp-Phe-NH2 analog and its synthetic method of the esterification modification of C- terminal aromatics and application 哈尔滨工业大学 2018-06-01 CN disclosed
CN-104704129-A Mutations associated with resistance to Bruton's tyrosine kinase (BTK) inhibitors PHARMACYCLICS INC 2015-06-10 CN disclosed
CN-101351561-A A method of measuring enzymatic activity of adsorbed allergenic enzyme ALK ABELLO AS (DK) 2009-01-21 CN disclosed
EP-1135398-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION Monsanto Technology LLC (US) 2001-09-26 EP disclosed
US-6218563-B1 Cyanophosphonamides and method for preparation MONSANTO COMPANY 2001-04-17 US disclosed
WO-2000032611-A1 CYANOPHOSPHONAMIDES AND METHOD FOR PREPARATION MONSANTO TECHNOLOGY LLC (US) 2000-06-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210379052-A1 QUINOLINE DERIVATIVE HAVING INDOLEAMINE-2,3-DIOXYGENASE INHIBITORY ACTIVITY IDO1, IDO2, INMT KDM4E 106/4885MAPT 3101/4885MEN1 3118/4885
US-11845808-B2 Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases IL23R, IL1RN, VIP KDM4E 4705/4885MAPT 2759/4885MEN1 3503/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.